AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $198.07M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.79M
Average 0.29M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$5.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
SAB Biotherapeutics, Inc. NASDAQ:SABS | $266.66M | $2.96 | Not rated | 3.0 | -23.42% |
Q32 Bio Inc. NASDAQ:QTTB | $260.64M | $8.71 | Not rated | 5.4 | +339.38% |
Verrica Pharmaceuticals Inc. NASDAQ:VRCA | $61.16M | $3.56 | Not rated | -3.5 | -21.89% |
Boundless Bio, Inc. NASDAQ:BOLD | $59.03M | $2.50 | Not rated | -1.0 | +114.41% |
iBio, Inc. NASDAQ:IBIO | $51.55M | $0.73 | Not rated | -3.6 | -19.51% |
Continue the stock analysis
Jump to another research area for this company.